













□□□□ Double-blind Trial□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Single-blind Trial□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Open-label Trial□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Allocation Concealment□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□ Allocation Schedule□	□□□□□□□□□□□□□□□□□□
□□□□ Single-dummy□	□□□□□□□□□□□□□□□□□□ □
□□□□ Double-dummy□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Drug Coding□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Maintenance of Blind□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□□□ Blinded Data Review□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□ Unblinding□	□□□□□□□□□□□□□□□□□□
□□□□ Unblinding at the End□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□
□□□□□□ Unblinding for Interim Analysis□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□
□□□□ Emergent Unblinding□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□□ Unintentional/Accidental Unblinding□	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□

??????

□□	□□
□□□□	Placebo-dummy

□□□□□	Standard Operation Procedure, SOP
□□□□	Single-blind Trial
□□□	Single-dummy
□□□□□	Electronic Data Capture, EDC
□□□□	Independent Review
□□□□□□	Independent Review Committee, IRC
□□□□□□	Unblinded Interim Analysis
□□□□	Allocation Concealment
□□□□□	Patient Reported Outcome, PRO
□□□□	Encryption Technology
□□□□□□	Interactive Response System, IRS
□□	Unblinding
□□□□	Emergent Unblinding
□□□□	Open-label Trial
□□□	Auditor
□□□	Clinical Research Associate, CRA
□□□□□	Clinical Research Coordinator, CRC
□□	Allocation Schedule
□□	Blinding/Masking
□□□□	Blinding Monitoring
□□□□	Maintenance of Blind
□□□□□□	Blinded Data Review
□□□□□□	Unblinding for Interim Analysis
□□□□□	Blockchain Technology
□□□□□□□	Data Monitoring Committee, DMC
□□□□	Double-blind Trial
□□□	Double-dummy
□□□□□	Internet of Things Technology
□□□□□□	Modern Logistics Technology
□□□□□□	Serious Adverse Event, SAE
□□□□	Drug Coding
□□□□	Unintentional/Accidental Unblinding

